Design, Synthesis, and Testing of Breast Cancer Angiogenesis Inhibitors
Abstract
Tumor angiogenesis is the process by which a growing tumor mass recruits the new blood vessels required for its continued growth, and through which the tumor can spread to distant sites. Indeed the neovascularization process is thought to be one of the rate limiting steps for the growth of primary and metastatic breast tumors. This proposal will focus on the development of inhibitors of a particular angiogenic factor, thymidine phosphorylase/platelet-derived endothelial cell growth factor (TP/PD-ECGF). These inhibitors will target the enzymatic activity of TP/PD-ECGF, since it has been found to be required for angiogenesis. In the past year, several compounds have been synthesized, with one showing good enzyme inhibitory activity in vitro (IC60 =30 microM). These compounds will form the basis for further exploration of structure-activity relationships.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 1997
- Accession Number
- ADB232089
Entities
People
- Edward L. Schwartz